Importancia del estado nutricional en el paciente con cáncer

  1. López Carrizosa, Concepción 1
  2. Samper Ots, Pilar 1
  3. Martín de Miguel, Manuel Joaquín 1
  4. Rodríguez Pérez, Antonio 1
  5. Vallejo Ocaña, Carmen 1
  6. Sáez Garrido, Juan de Dios 1
  7. Delgado Pérez, José María 1
  1. 1 Hospital Central de la Defensa
    info
    Hospital Central de la Defensa

    Madrid, España

    ROR https://ror.org/050qbxj48

    Geographic location of the organization Hospital Central de la Defensa
Journal:
Oncología

ISSN: 0378-4835

Year of publication: 2003

Volume: 26

Issue: 8

Pages: 23-37

Type: Article

SCOPUS: 2-s2.0-0344012545 DIALNET GOOGLE SCHOLAR

More publications in: Oncología

Abstract

The inability to sustain an appropriate nutritional status is a common problem in oncology patients. Both the neoplastic disease and its treatment lead to severe protein-caloric malnutrition which has prognostic significance. In this article, we review the pathophysiology of cancer cachexia and the local, systemic and secondary effects, such as the nutrition-associated complications of patients undergoing antitumor therapy. Despite the controversy surrounding the final benefit of pharmacologic management and nutritional support of anorexia/caquexia, we evaluate the potential methods and we conclude that the nutritional assessment should be part of cancer treatment in order to improve the outcome and to limit the complications. We have a simple, sensitive and specific method to evaluate it: The Subjective Global Assessment of nutritional status.

Bibliographic References

  • Aisner J, Parnes H, Tchekmedyian NS. Appetite stimulation and weight grain with megestrol acetate. Seminars in Oncology, 1990; 17, 6(suppl.9): 2-7.
  • Axelrod L, Costa G. The contribution of fat loss to weight loss in cancer. Nutrition and Cancer 1980; 2(1):81-83.
  • Barber MD, Fearon KCH, Delmore G, et al. Should cancer patients with incurable disease receive parenteral or enteral nutrition support? Eur J Cancer 1998; 34(4): 279-85.
  • Barber MD, Ross JA, Voss AC, et al. The effect of an oral nutritional supplement enriched with fish oil on weight-loss in patients with pancreatic cancer. British Journal of Nutrition 1999; 81:80-86.
  • Beller E, Tattersall M, Lumley T, et al. Improved quality of life with megestrol acetate in patients with endocrine-insensitive advanced cancer: a randomised placebo-controlled trial. Ann. Oncol. 1997; 8:277-283.
  • Bernstein IL. Physiological and psychological mechanisms of cancer anorexia. Cancer Research 1982; 42(2, Suppl): 715s-720s.
  • Blackburn GL, Bistrian BR, Maini BS, et al. Nutritional and metabolic assessment of the hospitalized patient. Journal of Parenteral and Enteral Nutrition 1977; 1(1): 11-22.
  • Bloch AS. Nutrition Management of the Cancer Patient. Rockville, Maryland: Aspen Publishers, 1990.
  • Brennan MF, Pisters PW, Posner M, et al. A prospective randomised trial of total parenteral nutrition after major pancreatic resection for malignancy. Ann Surg 1994; 220:436-41.
  • Bruera E, Ernst S, Hagen N, et al. Effectiveness of megestrol acetate in Patient with advanced cancer: a randomized, double-blind, crossover study. Cancer Prev. Control. 1998; 2 (2): 74-78.
  • Bruera E. Current pharmacological management of anorexia in cancer patients. Oncology (Huntington NY) 1992; 6(1): 125-130.
  • Bruera E. Pharmacological treatment of cachexia: any progress? Supp. Care Cancer, 1998; 6:109-113.
  • Cariuk P, Lorite MJ, Field WN, et al. Induction of in mice by a product isolated from the urine of cachectic cancer patients. Br J Can 1997; 76 (5):606-13.
  • Chen HC, Wan Leung S, Wang CJ, et al. Effect of megestrol acetate and prepulsid on nutricional improvement in patients with head and neck cancers undergoing radiotherapy. Rad. Oncol. 1997; 43:75-79.
  • Chlebowski RT, Palomares MR, Lillington L, et al. recent implications of weight loss in lung cancer management. Nutrition 1996; 12(1):43s-47s.
  • Chlebowski RT. Critical evaluation of the role of nutritional support with chemotherapy. Cancer 1985; 55(1, Suppl): 268-272.
  • Clark J, McGee R, Preston R. Nursing management of responses to the cancer experience: nutrition. In: Clark J, McGee R, Eds.: Core Curriculum for Oncology Nursing. Philadelphia: W.B. Saunders, 1992, pp 93-106.
  • Copeland EM, Daly JM, Dudrick SJ. Nutrition as an adjunct to cancer treatment in the adult. Cancer Research 1977; 37(7, Part 2):2451-2456.
  • Costa G. Caquexia, the metabolic component of neoplastic disease. Cancer Res, 1977; 37: 2327-2335.
  • De Wys WD, Begg C, Lavin PT, et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. American Journal of Medicine 1980; 69(4): 491-497.
  • Detsky AS, Baker JP, O'Rourke K, et al. Perioperative parenteral nutrition: A meta-analysis. Ann Int Med 1987; 107:195-203.
  • Detsky AS, Baker JP, O'Rourke K, et al. Predicting nutrition-associated complications for patients undergoing gastrointestinal surgery. Journal of Parenteral and Enteral Nutrition 1987; 11 (5): 440-446.
  • Detsky AS, McLaughlin JR, Baker JP, et al. What is subjective global assessment of nutritional status? Journal of Parenteral and Enteral Nutrition 1987; 11(1): 8-13.
  • DeWys WD, Begg C, Band P, et al. The impact of malnutrition on treatment results in breast cancer. Cancer Treatment Reports 1981; 65(Suppl 5):87-91.
  • Donoghue M, Nunnally C, Yasko JM. Nutritional Aspects of Cancer Care. Reston, VA: Reston Publishing Company, Inc., 1982.
  • Evans WK, et al. A randomised study of oral nutrition support versus ad lib nutritional intake during chemotherapy for advancer colorrectal and non small-cell lung cancer. J Clin Oncol 1987; 5:113-24.
  • Falconer JS, Fearon KCH, Plester CE, et al. Cytokines, the acute-phase response, and resting energy expenditure in cachectic patients with pancreatic cancer. Ann Surg 1994; 219(4):325-31.
  • Falconer JS, Fearon KCH, Ross JA, et al. acute-phase response and survival duration of patients with pancreatic cancer. Cancer 1995; 75(8):2077-82.
  • Feliu J, González-Barón M, Berrocal A, et al. Usefulness of megestrol acetate in cancer cachexia and anorexia. Am. J. Clin. Oncol. 1992; 15:436-440.
  • Gagnon B, Bruera E. A review of the drug Treatment of caquexia associated with cancer. Drugs, 1998; 55 (5):675-688.
  • Goodlad GA, Clark CM. Protein metabolism in the tumour-bearing host. Acta Chirurgica Scandinavica Supplementum 1980; (498):137-140.
  • Hays DM, Merritt RJ, White L, et al. Effect of total parenteral nutrition on marrow recovery during induction therapy for acute nonlymphocytic leukemia in childhood. Medical and Pediatric Oncology 1983; 11(2): 134-140.
  • Hirsch S, de Obaldia N, Petermann M, et al. Subjective global assessment of nutritional status: further validation. Nutrition 1991; 7(1): 35-38.
  • Holroyde CP, et. al. Anormalidades metabólicas generales en pacientes con cancer: anorexia-cáncer. En: Nutrición y cáncer I. Clin. Quir. North. Am., 1986; 6: 963-971.
  • Hyltander A, Korner U, Lundholm KG. Evaluation of mechanism behind elevated energy expenditure in cancer patients with solid tumors. Eur J Clin Invest 1993; 23: 46-52.
  • Jatoi A, Kumar S, Sloan JA, Nguyen PL. On appetite and its loss. J. Clin. Oncol. 2000; 18(15):2930-2932.
  • Kokal WA. The impact of antitumor therapy on nutrition. Cancer 1985; 55(1, Suppl):273-278.
  • Kosty MP, Fleishman SB, Herndon JE, et al. Cisplatin, vinblastine, and hydrazine sulfate in advanced, non-small-cell lung cancer: a randomized placebo-controlled, double-blind phase III study of the Cancer and Leukemia Group B. Journal of Clinical Oncology 1994; 12(6):1113-1120.
  • Langstein HN, Norton JA. Mechanisms of cancer cachexia. Hematology/Oncology Clinics of North America 1991; 5(1): 103-123.
  • Lindsey AM, Piper BF, Stotts NA. The phenomenon of cancer cachexia: a review. Oncology Nursing Forum 1982; 9(2): 38-42.
  • Lindsey AM. Cancer cachexia: effects of the disease and its treatment. Seminars in Oncology Nursing 1986; 2(1):19-29.
  • Loprinzi CL, Goldberg RM, Su JQ, et al. Placebo-controlled trial of hydrazine sulfate in patients with newly diagnosed non-small-cell lung cancer. Journal of Clinical Oncology 1994; 12(6):1126-1129.
  • Loprinzi CL, Kugler JA, Sloan JA, et al. Randomized comparison of megestrol acetate versus dexametasone versus fluoxymesterone for the treatment of cancer anorexia / caquexia. J. Clin. Oncol. 1999; 17(10): 3299-3306.
  • Loprinzi CL, Kuross SA, O'Fallon JR, et al. Randomized placebo-controlled evaluation of hydrazine sulfate in patients with advanced colorectal cancer. Journal of Clinical Oncology 1994; 12(6):1121-1125.
  • Loprinzi CL, Mailliard J, Schaid DJ, et al. Dose / response evaluation of megestrol acetate for the treatment of anorexia and cachexia: a Mayo Clinic and North Central Cancer Treatment Group trial. Proc. Am. Sac. Clin. Oncol. 1992; 11: 378 (Abstrac 1308).
  • Loprinzi CL, Michalak JC, Schaid DJ, et al. Phase III evaluation of four doses of Megestrol acetate as therapy for patients with cancer anorexia and / or caquexia. J. Clin. Oncol. 1993; 11(4):762-767.
  • Mc Geer AJ, Detsky AS, O'Rourke K. Parenteral nutrition in cancer patients undergoing chemotherapy: A meta-analysis. Nutrition 1990; 6:233-40.
  • McDevitt TM, Todorov PT, Beck SA, et al. Purification and characterizacion of a lipid-mobilizing factor associated with inducing tumors in mice and humans. Cancer Research 1995; 55: 1458-1463.
  • Muller JM, Brenner U, Dienst C, et al. Preoperative parenteral feeding in patients with gastrointestinal carcinoma. Lancet 1982; 1:68-71
  • Nelson KA, Walsh D, Sheehan FA. The cancer anorexia-cachexia syndrome. Journal of Clinical Oncology 1994; 12(1): 213-225.
  • Nixon DN, Heymsfield SD, Cohen AE, et al. Protein-calorie undernutrition in hospitalized cancer Patient. Am. J. Med., 1980; 68: 683-690.
  • Norton JA, Moley JF, Green MV, et al. Parabiotic transfer of cancer anorexia/in male rats. Cancer Research 1985; 45:55477-52.
  • Ottery D, Walsh D, Strawford A. Pharmacologic management of anorexia / caquexia. Sem. Oncol. 1998; 25(Suppl 6):35-44.
  • Ottery FD. Cancer cachexia: prevention, early diagnosis, and management. Cancer Practice 1994; 2(2):123-131.
  • Ottery FD. Rethinking nutritional support of the cancer patient: the new field of nutritional oncology. Semin. Oncol. 1994; 21:770-778.
  • Ottery FD. Supportive nutrition to prevent cachexia and improve quality of life. Semin. Oncol. 1995; 22:98-111.
  • Ovensen L, Allingstrup L, Hannibal J, et al. Effect of dietary counselling on food intake, body weight, response rate, survival, and quality of life in cancer patients undergoing chemotherapy: A prospective, randomised study. J Clin Oncol 1993; 11:2043-49.
  • Padilla GV, Grant MM. Psychosocial aspects of artificial feeding. Cancer 1985; 55(1, Suppl):301-304.
  • Padilla GV, Presant C, Grant MM, et al. Quality of life index for patients with cancer. Research in Nursing and Health 1983; 6(3):117-126.
  • Parnes H, Tait N, Aisner J. The potential of megestrol acetate in the treatment of cancer cachexia. Nutrition 1989; 5(3):206-209.
  • Reilly JJ, Hull SF, Albert N, et al. Economic impact of malnutrition: a model system for hospitalized patients. Journal of Parenteral and Enteral Nutrition 1988; 12(4): 371-376.
  • Rivadeneira DE, Evoy D, Fahey, et al. Nutritional support of the cancer patient. Cancer Journal Clinician 1998; 48(2):69-80.
  • Robinson G, Goldstein M, Levine GM. Impact of nutritional status on DRG length of stay. Journal of Parenteral and Enteral Nutrition 1987; 11(1):49-51.
  • Rombeau JL, Caldwell MD, Eds. Clinical Nutrition: Parenteral Nutrition. Philadelphia: Saunders, 2nd ed., 1993.
  • Rumley TO, Copeland EM. Valor del sostén nutricional en pacientes cancerosos adultos. En: Nutrición y cáncer II (ed. Espa.). Clin. Quir. North. Am., 1986; 6: 1175-1192.
  • Shaw MT, et. al. Effects of cancer, radiotherapy and cytotoxic drugs on intestinal structure and function cancer treat. Reu., 1979; 6:141-151.
  • Smith SA. Theories and intervention of nutritional deficit in neoplastic disease. Oncology Nursing Forum 1982; 9(2): 43-46.
  • Staal-van den Brekel AG, Dentener Ma, Schols AMWJ. Increased resting energy expenditure and weight loss are related to a systemic inflammatory response in lung cancer patients. J Clin Oncol 1995; 13(10):2600-05.
  • Strassman G, Fong M, Kenney JS, et al. Evidence for the involvement of interleukin-6 in experimental cancer. J Clin Invest 1992; 89:1681-84.
  • Studley HO. Percentage of weight loss: a basic indicator of surgical risk in patients with chronic peptic ulcer. Journal of the American Medical Association 1936; 106(6): 458-460.
  • Szeluga DJ, Groenwald SL, Sullivan DK. Nutritional disturbances. In: Groenwald SL, Frogge MH, Goodman M, et al.: Cancer Nursing: Principles and Practice. Boston: Jones and Bartlett Publishers, 2nd Edition, 1990; 495-519.
  • Tchekmedyian NS, Hickman M, Siau J, et al. Treatment of cancer anorexia with megestrol acetate: impact on quality of life. Oncology (Huntington NY) 1990. 4(5): 185-192.
  • Theologides A. Cancer cachexia. Current Concepts in Nutrition 1977; 6: 75-94.
  • Tisdale M. Metabolic abnormalities in and anorexia. Nutrition 2000; 16:1013-14.
  • Tisdale MJ, Beck S. Inhibition of tumor- induced lipolysis in vitro and tumor growth in vivo by eicosapentanoic acid. Biochem Pharmacology 1991; 41:103-107.
  • Tisdale MJ. Cancer cachexia. Anti-Cancer Drugs 1993; 4: 115-125.
  • Tisdale MJ. Inhibition af lipolysis and muscle protein degradation by EPA in cancer. Nutrition 1996; 12:S31-S33
  • Todorov PT, McDevitt TM, Cariuk P, et al. Induction of muscle protein degradation and weight loss by a tumor product. Cancer Research 1996; 56:1256-61.
  • Tubiana M, Attie E, Flamant R, et al. Prognostic factors in 454 cases of Hodgkin's disease. Cancer Research 1971; 31:1801-1810.
  • Waterhouse C. Oxidation and metabolic interconversion in malignant cachexia. Cancer Treatment Reports 1981; 65(Suppl 5):61-66.
  • Westman G, Bergman B, Albertsson M, et al. Megestrol acetate in advanced, progressive, hormone-intensitive cancer. Effects on the Quality of life: a placebo-controlled, randomised, multicentre trial. Eur. J. Cancer 1999; 35 (4):586-595.
  • Wigmore SJ, Fearon KCH, Maingay JP, et al. Interleukin-8 can mediate acute-phase protein production by isolated human hepatocytes. Am J Physiol 1997; 273: E270-E26.
  • Wigmore SJ, Plester CE, Richardson RA. Changes in nutritional status associated with unresectable pancreatic cancer. Br J Cancer 1997; 75: 106-09.
Data source: Dialnet